atibuclimab

A recombinant chimeric monoclonal antibody against human CD14, with potential anti-inflammatory and immunomodulating activities. Upon administration, atibuclimab binds to and neutralizes CD14, and prevents the interactions of CD14 with pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) resulting from bacterial and viral infection. This prevents membrane and soluble CD14-mediated signaling and inflammatory cascade, and prevents cytokine release, granulocyte activation, and the resulting tissue and organ injury. CD14, a protein involved in the innate recognition of many pathogens including bacteria and viruses, is expressed on the surface of monocytes and neutrophils and present in the blood and lung fluids as a soluble isoform. This allows CD14 to amplify inflammatory responses in multiple sites in the body which help fight infections, however, it may sometimes lead to overreaction and tissue and organ injury.